|
HPV ctDNA analysis in unresectable recurrent/metastatic oropharyngeal cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bristol-Myers Squibb |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; CUE Biopharma; Eisai; LOXO; Merck Sharp & Dohme |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; CUE Biopharma; Eisai; Loxo; Merck; Rakuten Medical |
Research Funding - Bristol-Myers Squibb; Eisai (Inst); Lilly; Loxo; Merck (Inst); Oragenics; Pfizer (Inst) |
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Regeneron |
Research Funding - Ascentage Pharma Group; Pfizer |